Federal regulators have begun reviewing applications from Swiss drugmaker Sandoz to develop generic versions of tirzepatide medicines sold as Mounjaro and Zepbound. If approved, those generics would offer lower-cost alternatives to the branded GLP-1 therapies now widely used for type 2 diabetes and obesity.
The U.S. Food and Drug Administration has accepted Sandoz’s submissions and placed them in the agency’s standard review process. The FDA does not promise a fixed timeline for every application, but its typical review window for standard drug approvals is about 10 months.
Sandoz seeks approval for generic, once-weekly injectable versions intended for the same uses as the brand-name products. Mounjaro is marketed for type 2 diabetes, while Zepbound is authorized for obesity (and has an indication that includes sleep apnea). The company says its product would be prescribed alongside lifestyle measures such as diet and exercise, the same approach recommended with the branded drugs.
Cost is a major part of the motivation for generics. Branded tirzepatide medicines can cost more than $1,000 per month without insurance; Sandoz estimates its generic would run roughly $200 to $400 monthly for uninsured patients. Generic manufacturers typically avoid the large initial research costs that brand companies shoulder, allowing lower price points.
However, patent protections affect when generics can reach the U.S. market. Eli Lilly holds patents on Mounjaro and Zepbound that extend in the United States through 2036. That means generic tirzepatide products generally cannot be sold in the U.S. until patent expiration unless a court or the FDA allows an exception. Patents are expiring earlier in some other countries, which is driving a global race among companies to introduce generic GLP-1 drugs.
There has been precedent for temporary access outside standard approval pathways: during a GLP-1 shortage in late 2022 the FDA allowed certain compounded alternatives, but that allowance ended in December 2024 when the agency determined supply had stabilized.
Outside the U.S., generics are already advancing. For example, Canadian regulators recently approved an injectable generic semaglutide product to treat weight loss, illustrating how competition is expanding internationally.
Clinicians and experts say affordable generics could widen access and ease supply constraints. Physicians note the high cost of brand GLP-1s is a primary barrier to starting and staying on treatment; lower-priced generics would make long-term use more feasible and could encourage insurance coverage for cheaper alternatives. Many expect generics to match branded drugs in effectiveness when manufactured and regulated to the same standards.
How these drugs work and what to expect
GLP-1 and related drugs, including tirzepatide, act on appetite regulation and blood sugar control. They are used both to help patients with type 2 diabetes manage glucose levels and, in other formulations, to support medically supervised weight loss. Most of the newer agents are given as weekly injections, though oral versions of some GLP-1s have been approved as daily pills.
These medications can produce meaningful reductions in weight and improvements in metabolic health, including favorable effects on blood pressure and cholesterol that may lower cardiovascular risk. But they are not side-effect free. Common adverse effects include nausea, headache, abdominal pain, heartburn, dizziness, and mood changes. Clinicians emphasize that GLP-1s work best as part of a long-term treatment plan that includes dietary changes, aerobic and resistance exercise, and ongoing medical follow-up.
The larger picture
If Sandoz’s tirzepatide generics and other competitors reach the market, the result could be lower prices, improved availability, and broader insurance acceptance—especially outside the U.S. where patents have already lapsed. For patients who benefit from these medicines, more affordable options would make sustained treatment more attainable, helping more people manage diabetes and obesity over the long term.
Regulatory steps remain: FDA review is underway, and U.S. patent protections mean broad domestic availability may be years away unless legal or regulatory exceptions occur. Still, the move by a major generic manufacturer marks a significant step in the growing effort to increase competition and affordability in the GLP-1 drug class.